Trevi Therapeutics, Inc.
TRVI
$14.76
-$0.12-0.81%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 3.67% | 10.75% | -3.48% | -21.99% | -41.06% |
| Total Depreciation and Amortization | -5.37% | -2.04% | 4.86% | 4.20% | 7.19% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 56.84% | 48.86% | 80.55% | 81.72% | 198.29% |
| Change in Net Operating Assets | -271.61% | -151.14% | -133.69% | -69.12% | 233.11% |
| Cash from Operations | -9.78% | -10.02% | -25.50% | -30.18% | -21.44% |
| Capital Expenditure | -225.71% | 65.71% | 62.00% | 89.71% | 56.25% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -187.23% | -337.79% | -673.21% | -212.46% | -155.01% |
| Cash from Investing | -187.29% | -337.14% | -675.23% | -212.79% | -155.19% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 100.00% | 91.27% | 66.93% | 41.27% | 98.65% |
| Issuance of Common Stock | 59.32% | 96.57% | 1,598.09% | 2,472.02% | 3,832.22% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 162.16% | -- | -44.83% | -156.52% | 8.64% |
| Cash from Financing | 60.26% | 96.82% | 1,628.35% | 2,602.77% | 1,226.17% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -99.32% | -993.12% | 511.75% | 13,293.28% | 157.55% |